Title of the cohort
Cohort – Cardiovascular Risk Factors in Aging and Dementia
Acronym for cohort
CAIDE
Name of Principal Investigator
| Title | Docent, Ass Professor |
| First name | Miia |
| Last name | Kivipelto |
Address of institution where award is held
| Institution | University of Eastern Finland |
| Street Address | Yliopistonranta 1 B |
| City | Kuopio |
| Postcode | 70211 |
Country
- Finland
Website
www.uef.fi/caide
Contact email
Funding source
Acedemy of Finland
1. The cohort includes, or expects to include, incidence of the following conditions
- Alzheimer’s disease and other dementias
When studies on the above condition(s) are expected to become possible
- Already possible
2a. Stated aim of the cohort
To investigate cardiovascular and life style risk factors for dementia / Alzheimer’s disease.
2b. Features distinguishing this cohort from other population cohorts
A population based longitudinal study with 28 years follow-up that also provides data concerning midlife risk factors for late life dementia.
3a. i) Number of publications that involve use of cohort to date
20
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
Kivipelto et al BMJ 2001
Kivipelto et al Lancet Neurology 2006
3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment
| Age in years from: | About 50 years |
| To (‘until death’ if applicable): |
4b. Study criteria: inclusion criteria
Population based cohort
4c. Study criteria: exclusion criteria
Please see Kivipleto et al 2001
5. Size of the cohort (i.e. number of participants enrolled)
- 1,000 – 5,000 participants
6a. Measures used to characterise participants
Please see Kivipelto et al 2001
6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
Dementia, Specofic causes of dementia, MCI
7. Study design
- Prospective cohort
- Longitudinal
8. Cases matched by
- Age
9a. Does the study include a specialised subset of control participants
- Yes
9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date
01-01-1997
10a. ii) Data collection end date
01-01-2010
10a iii) Data collection for this study is
- Data analysis ongoing
- Closed to new patients
10b. Plans to continue the cohort study beyond the current projected end date
11. Data collected
- Through links to medical records
- Through links to other records or registers (such as dental records, police records etc). Please specify
- ###VALUE###
12. System in place to enable re-contact with patients for future studies
- Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)
13a. Format and availability of data stored in a database
| Yes/No | % available | |
| Data summarised in database | Yes | |
| Database is web-based | ||
| Database on spreadsheet | ||
| Database is on paper | Yes | |
| Other (specify) |
Language used:
Finnish /english
13b. Format and availability of data held as individual records
Language used:
14a. Are data available to other groups
Yes
14b. Access policy/mechanisms for access if data are available to other groups
- Access through collaboration with PI only
15. Data sharing policy specified as a condition of use
- No requirement to make data publicly available
16a. Are tissues/samples/DNA available to other groups
No
16b. i) Description of available tissues/samples/DNA
- Living donors:blood
- Living donors: DNA
16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
Yes
17. Is information on biological characteristics available to other groups
- If available for a subset please specify number of patients and % of total cohort
- According to collaboration